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Introduction
The early repolarization pattern (ERP) is a common ECG finding characterized by an elevation at the QRS-
ST junction (J point) of  at least 0.1 mV in 2 adjacent ECG leads. The prevalence of  ERP in the general popu-
lation ranges from 2% to 13% and is more common in young athletic men (1–5). The classical notion of  ERP 
being a benign ECG phenotype was challenged in 2008 by a landmark study by Haïssaguerre and colleagues 
showing an association of  ERP with increased risk of  ventricular fibrillation and sudden cardiac death (6): 
the early repolarization syndrome (ERS) (7). Since then, several studies have demonstrated an elevated risk 
of  cardiovascular and all-cause mortality in individuals with ERP, underscoring its arrhythmogenic potential 
(2, 8, 9). Although the mechanistic basis for malignant arrhythmias in ERS is unclear, it has been suggested 
that they occur as a result of  an augmented transmural electrical dispersion of  repolarization (10). Ex vivo 
studies point toward a central role of  the cardiac transient outward potassium current (Ito) in the develop-
ment of  both ERP and ERS (11). Furthermore, candidate genetic association studies have highlighted a role 
for several genes encoding cardiac ion channels in the development of  ERP and ERS (12–15). These genes 
include gain-of-function variants in IK-ATP channels (KCNJ8, ABCC9) and loss-of-function variants in car-
diac L-type calcium channels (CACNA1C, CACNB2b, CACNA2D1) and sodium channels (SCN5A, SCN10A) 
(16). Interestingly, coexistence of  2 genetic variants in different ion channel genes with opposing effects can 
be observed leading to phenotypic incomplete penetrance of  ERP (15). However, data from functional stud-
ies confirming causality are scarce (17).
Studies among first-degree relatives of  patients with sudden arrhythmic death syndrome show that 
ERP is more prevalent in family members than in controls, indicating that ERP is an important potentially 
inheritable proarrhythmic trait (18, 19). Moreover, in family studies, the heritability estimate for the pres-
ence of  ERP was h2 = 0.49 (20). However, estimates for common SNP heritability from unrelated individ-
uals are lower (21). This may explain why the only GWAS on ERP to date failed to identify genetic vari-
ants reaching genome-wide significance (22) and indicates the need for larger GWAS with more power.
In order to identify genetic variations that convey susceptibility to ERP, we performed a GWAS and 
meta-analysis in individuals with European ancestry, comprising 2,181 ERP cases and 23,641 controls 
from 8 cohorts that formed the discovery stage. The findings were taken forward to a replication stage in 
1,124 cases and 12,510 controls from an 4 additional cohorts. To maximize statistical power for locus dis-
covery, we subsequently performed a combined discovery and replication cohort GWAS meta-analysis of  
3,305 ERP cases and 36,151 controls.
BACKGROUND. The presence of an early repolarization pattern (ERP) on the surface ECG is 
associated with risk of ventricular fibrillation and sudden cardiac death. Family studies have shown 
that ERP is a highly heritable trait, but molecular genetic determinants are unknown.
METHODS. To identify genetic susceptibility loci for ERP, we performed a GWAS and meta-analysis 
in 2,181 cases and 23,641 controls of European ancestry.
RESULTS. We identified a genome-wide significant (P < 5 × 10–8) locus in the potassium voltage-
gated channel subfamily D member 3 (KCND3) gene that was successfully replicated in additional 
1,124 cases and 12,510 controls. A subsequent joint meta-analysis of the discovery and replication 
cohorts identified rs1545300 as the lead SNP at the KCND3 locus (OR 0.82 per minor T allele, P = 7.7 
× 10–12) but did not reveal additional loci. Colocalization analyses indicate causal effects of KCND3 
gene expression levels on ERP in both cardiac left ventricle and tibial artery.
CONCLUSIONS. In this study, we identified for the first time to our knowledge a genome-wide 
significant association of a genetic variant with ERP. Our findings of a locus in the KCND3 gene 
provide insights not only into the genetic determinants but also into the pathophysiological 
mechanism of ERP, discovering a promising candidate for functional studies.
FUNDING. This project was funded by the German Center for Cardiovascular Research (DZHK 
Shared Expertise SE081 – STATS). For detailed funding information per study, see the Supplemental 
Acknowledgments.
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Results
Clinical characteristics of  the study cohorts are depicted in Table 1. The proportion of  ERP based on the 
definition by Haïssaguerre and Macfarlane (6, 23) ranged from 6% to 14%, which is in line with the previ-
ously reported prevalence in the general population (2–4).
Variants associated with ERP. In the first stage, we performed a GWAS meta-analysis in up to 2,181 cases 
and 23,641 controls from 8 discovery cohorts. In total, 6,976,246 SNPs passed quality control (see Methods). 
We identified 19 variants spanning 49 kb in potassium voltage-gated channel subfamily D member 3 (KCND3) 
as well as rs139772527 (effect allele frequency [EAF] 1.4%, OR = 2.57, P = 2.0 × 10–8) near hemoglobin 
subunit zeta (HBZ) as being genome-wide significantly associated (P < 5 × 10–8) with ERP. The SNP with the 
lowest P value in the region (the lead SNP) at KCND3 was the intronic rs12090194 (EAF 32.5%, OR = 0.80, P 
= 4.6 × 10–10), and this SNP was replicated in an independent sample of  1,124 cases and 12,510 controls from 
4 additional cohorts (Preplication = 2.5 × 10
–3, Pcombined = 9.3 × 10
–12; Table 2). The SNP rs139772527 near HBZ did 
not fulfil the criteria for replication (Preplication = 0.28, Pcombined = 1.4 × 10
–6; Table 2), as described in the Meth-
ods. The subsequent combined meta-analysis of  all 12 cohorts, including up to 39,456 individuals, revealed 
only the locus at KCND3 to be genome-wide significantly associated with ERP (Supplemental Figure 1; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.131156DS1). 
The lead SNP of the combined GWAS meta-analysis was rs1545300 (EAF 31.9%, OR = 0.82, P = 7.7 × 
10–12), followed by the discovery-stage lead SNP, rs12090194, which was in strong linkage disequilibrium (LD) 
with rs1545300 (r2 = 0.96, D′ = 1) (Figure 1). Both SNPs were imputed at very high confidence (imputation 
quality score >0.97) in all cohorts. The quantile-quantile plots did not show any inflation (individual study λGC 
between 0.81 and 1.03; median, 0.91; overall meta-analysis λGC = 1.02; LD score regression intercept, 1.01; see 
Methods) (Supplemental Figure 2). The result of the combined GWAS meta-analysis was used for the sub-
sequent analyses. Summary statistics based conditional analysis to select independent hits did not reveal any 
Table 1. Baseline characteristics of the study populations
Study Subgroup No. of samples
(n)
No. of females
(n)
Age in years
(mean ± SD)
Heart rate in bpm 
(mean ± SD)
BMI
(mean ± SD)
Discovery stage
BRIGHT ERP+ 189 105 57.6 ± 12.1 61.7 ± 9.9 27.7 ± 3.4
ERP– 1173 747 59.4 ± 12.3 63.7 ± 11.2 27.4 ± 3.8
GHS1 ERP+ 182 60 54.5 ± 10.0 67.6 ± 11.5 26.8 ± 4.4
ERP– 2628 1358 55.6 ± 10.9 69.1 ± 10.8 27.1 ± 4.7
GHS2 ERP+ 70 26 54.0 ± 10.2 67.1 ± 11.4 27.5 ± 5.5
ERP– 1028 536 54.9 ± 10.9 68.7 ± 10.8 27.2 ± 4.9
GRAPHIC ERP+ 57 18 52.3 ± 3.9 63.5 ± 8.0 27.4 ± 4.0
ERP– 893 457 52.8 ± 4.5 64.1 ± 9.8 27.4 ± 4.3
Lifelines ERP+ 1253 639 48.0 ± 11.5 66.3 ± 10.9 25.7 ± 3.8
ERP– 11463 6902 47.9 ± 11.3 68.4 ± 11.5 26.4 ± 4.3
SHIP ERP+ 173 79 46.6 ± 16.1 70.5 ± 11.6 25.9 ± 4.2
ERP– 2835 1508 48.5 ± 15.8 73.7 ± 11.6 27.3 ± 4.9
SHIP-Trend ERP+ 86 38 49.8 ± 14.5 64.4 ± 8.9 26.9 ± 4.4
ERP– 848 494 49.7 ± 13.4 65.9 ± 9.6 27.3 ± 4.6
TwinsUK ERP+ 171 150 51.7 ± 13.2 64.1 ± 10.3 25.3 ± 4.4
ERP– 2773 2651 52.7 ± 12.4 66.8 ± 10.4 25.7 ± 4.6
Replication stage
CHRIS ERP+ 427 159 45.2 ± 16.3 60.3 ± 8.9 25.4 ± 4.2
ERP– 3953 2318 45.7 ± 16.1 62.5 ± 8.8 25.6 ± 4.6
Rotterdam Study I ERP+ 308 182 66.4 ± 7.6 68.7 ± 11.6 27.5 ± 7.4
ERP– 4438 2739 66.3 ± 7.7 69.2 ± 11.9 27.1 ± 6.9
Rotterdam Study II ERP+ 164 84 64.1 ± 7.3 67.5 ± 10.6 27.5 ± 4.1
ERP– 1476 825 64.4 ± 7.5 68.8 ± 10.8 27.5 ± 4.1
Rotterdam Study III ERP+ 225 116 56.7 ± 5.6 69.0 ± 11.7 27.6 ± 4.9
ERP– 2643 1541 57.0 ± 6.7 69.6 ± 10.5 27.5 ± 5.0
ERP+, cases with early repolarization pattern; ERP–, controls.
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secondary signals. The association results for each stage of the lead SNPs with P < 1 × 10–6 in 
the discovery meta-analysis are provided in Supplemental Table 1.
Statistical fine mapping of  the associated locus. All significantly associated SNPs of  the 
combined GWAS meta-analysis were located within KCND3 and were intronic (Table 3 
and Figure 2). We used these results to assess whether a single SNP or set of  variants drive 
the association signal in KCND3 (credible set). The 99% credible set was computed based 
on approximate Bayes factors for each SNP, resulting for each in a set of  SNPs that with 
99% posterior probability contained the variant(s) driving the association signal. For the 
associated locus at KCND3 the credible set spanned 49 kb and contained 19 variants. The 2 
lead SNPs, rs1545300 and rs12090194, had a posterior probability of  21% and 19%, respec-
tively, whereas the former candidate SNP, rs17029069 (22), had a posterior probability of  
2% (Supplemental Table 2).
To test whether the association in KCND3 might be driven by heart rate or RR interval, 
we performed a sensitivity analysis in the 1,253 ERP cases and 11,463 controls of  the Life-
lines cohort, adjusting the genetic association of  rs1545300 additionally for these 2 traits in 
separate models. The effect estimates were virtually unchanged (OR = 0.78), with P = 1.2 
× 10–7 for both adjustments. In addition, we assessed whether the association of  rs1545300 
might be related to a specific ERP subtype, i.e., ST segment or ERP localization. In all 
subtype-stratified analyses, the 95% confidence intervals of  the effect sizes overlapped with 
the overall results, which did not point to a subtype driven signal (Supplemental Table 3).
Expression quantitative trait locus and colocalization. We searched the Genotype-Tissue 
Expression (GTEx) project database (24) to look for tissue-specific expression quantitative 
trait loci (eQTLs), including all genes in the vicinity of  ±1 Mb of  the lead SNP, rs1545300, 
and found an association with KCND3 expression levels in the tibial artery (P = 3.0 × 10–6, 
n = 388). Two additional eQTL associations of  rs1545300, at FDR < 0.2, across the 48 
tissues tested were found with KCND3 (ENSG00000171385.5) in the left ventricle (P = 2.9 
× 10–4, n = 272) of  the human heart and with CEPT1 (ENSG00000134255.9) in the minor 
salivary gland (P = 3.4 × 10–4, n = 85) (Supplemental Table 4).
Subsequent colocalization analyses of  rs1545300 in these 3 tissues revealed a signifi-
cant correlation of  gene expression pattern with ERP (PSMR ≤ 0.01) (Figure 3 and Supple-
mental Table 5), where for the left ventricle the correlation seems to be attributable to the 
same underlying causative variant (PHEIDI ≥ 0.05) and for tibial artery the test was close to 
nominal significance (PHEIDI = 0.05). However, the significant PHEIDI = 1.7 × 10
–3 for CEPT1 
in the minor salivary gland points rather toward a pleiotropic effect of  rs1545300 than a 
causal effect of  gene expression on ERP in this tissue. For all 3 tissues, an increased gene 
expression level was associated with a higher risk of  ERP (Supplemental Table 5).
Pleiotropic effects of  the lead SNPs. To assess pleiotropic effects of  the KCND3 lead SNP 
rs1545300 or its proxies (r2 > 0.8), we looked for genome-wide significant associations in the 
NHGRI-EBI catalog of  published GWAS (25) (accessed July 30, 2019). Pleiotropic associa-
tions were found for P wave terminal force (rs12090194 and rs4839185) (26) and for reduced 
risk of  atrial fibrillation per minor allele (rs1545300 and rs1443926) (27, 28). All these SNPs 
were in strong LD (r2 > 0.97) with the lead SNP. In addition, variants in low-to-moderate LD 
with rs1545300 were associated with P wave duration (rs2798334, r2 = 0.26) (29) and ST-T 
wave amplitudes (rs12145374, r2 = 0.60) (30). A phenome-wide lookup of  rs1545300 in the 
association results of  778 traits available via the Gene ATLAS web portal (31) using 452,264 
individuals from the UK Biobank cohort revealed an association of  the ERP risk–reducing 
minor T allele with reduced risk of  heart arrhythmia (estimated OR = 0.92, P = 3.6 × 10–6). 
Of  note, no other of  the assessed traits reached significance after Bonferroni correction (P < 
0.05 for the analyzed 778 traits = 6.4 × 10–5).
Discussion
In this GWAS meta-analysis comprising 3,305 cases and 36,151 controls, including indepen-
dent replication samples, we describe an association of ERP with a locus on chromosome 1 in 
the KCND3 gene. This is the first study to our knowledge that identifies a robust genome-wide Ta
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significant association between genetic variants and ERP. Our findings provide a candidate gene for further 
functional studies examining the pathophysiological mechanism of ERP and potentially ERS. The KCND3 
gene encodes the main pore-forming α subunit of the voltage-gated rapidly inactivating A-type potassium chan-
nel. In the cardiac ventricle KCND3 contributes to the fast cardiac transient outward potassium current (Ito), 
which plays a major role in the early repolarization phase 1 of the cardiac action potential (AP).
To date, two competing theories explain the presence of  J waves and ERP: the repolarization and 
the depolarization theory; both of  these involve the Ito channel. On the basis of  animal models, evi-
dence for the former is more compelling. Thus, J waves result from a transmural voltage gradient creat-
ed by a more prominent epicardial phase 1 AP notch relative to the endocardial AP notch (11, 32). The 
Ito current notably influences the degree of  the transmural heterogeneity of  the phase 1 AP notch and 
consecutively the magnitude of  the J wave (11, 32). Pharmacological inhibition of  the Ito current with 
4-aminopyridine results in a reduction of  the J wave amplitude (11). The depolarization theory is based 
on clinical overlap of  ERP with Brugada syndrome, which has led to the suggestion that Brugada syn-
drome is a right ventricular variant of  the ERP (33). In theory, deviation from the sequential activation 
of  cardiac currents INa, Ito, and ICaL can lead to regional conduction slowing and appearance of  inferior 
and/or lateral ERP (32, 34). In patients with ERS, distinct phenotypes of  both delayed depolarization 
and early repolarization have been identified (35).
ERP is a highly heritable trait within families (3, 20); however, limited heritability can be attribut-
ed to common SNPs in unrelated individuals (21). This might be a reason why the only GWAS to 
date that included 452 cases failed to replicate any genome-wide significant loci (22). In our study, 
which includes 3,334 cases, we discovered and replicated variants in the KCND3 gene. Interestingly, 
one of  these variants (rs17029069), which is in moderate LD (r2 = 0.18, D′ = –1) with our lead SNP, 
rs1545300 (Supplemental Figure 3), was reported as a candidate in the earlier GWAS meta-analysis 
(22). However, this variant did not replicate in their study; the authors attributed this finding to limited 
power based on the small sample size and/or heterogeneous phenotyping. In our study, experienced 
cardiologists evaluated more than 39,000 ECGs with high reproducibility ensuring a very high pheno-
typing quality (21). The resulting homogenously assessed phenotype and the substantially increased 
number of  cases are two aspects that elevated the statistical power of  our GWAS meta-analysis. All 
detected variants cluster in intronic regions of  the KCND3 gene, without significant allelic heteroge-
neity. The annotation of  the locus does not point to a direct pathogenic effect, i.e., a protein-altering 
mutation; additionally, the statistical fine mapping revealed no single SNP with a substantial posterior 
probability (e.g., >80%) of  being causal. However, the latter approach has limitations in detecting rare 
causal variants due to imputation uncertainty and minimum minor allele frequency (MAF). Neverthe-
less, eQTL analysis suggested that the detected variants may affect KCND3 gene expression. Potential 
mechanisms include modification of  gene expression via altered binding of  transcription factors at 
cis-elements through enhancers or in DNaseI hypersensitivity regions (Figure 2). This is supported 
by the results of  the test for colocalization, which showed an increase of  ERP risk due to increased 
KCND3 gene expression levels in tissues of  the human heart and tibial artery. Similar, pharmacological 
ex vivo data predict that gain-of-function mutations in the Ito current increase the overall transmural 
outward shift, leading to an increased epicardial AP notch and thereby inducing ERP in the surface 
ECG (32). Additionally, a long noncoding RNA (lncRNA), KCND3 antisense RNA 1 (KCND3-AS1), 
has been described to be in close proximity to the lead SNP, rs1545300 (Figure 2). lncRNAs have 
been shown to physiologically influence gene regulation through various mechanisms, e.g., chromatin 
remodeling, control of  transcription initiation, and posttranscriptional processing (36, 37). On the 
other hand, dysregulation of  lncRNA control circuits can potentially effect the development of  disease 
(38): a very prominent example of  this in cardiovascular diseases is the lncRNA ANRIL, which is a key 
effector of  9p21 in atherosclerotic risk and cardiovascular events (38–40).
Figure 1. GWAS results for the KCND3 locus. The results of the combined early repolarization pattern (ERP) GWAS results for the KCND3 locus are 
shown for the replicated discovery-stage lead SNP rs12090194 in n = 38,811 individuals (A and B) and for the combined GWAS lead SNP rs1545300 in n 
= 38,806 individuals (C and D). The regional association plots (A and C) show the association results in a ±500-kb region around the lead SNP. SNPs are 
plotted on the x axis according to their chromosomal position with the –log10(P value) of the GWAS association on the y axis. Correlation with the lead 
SNP (purple) is estimated based on the 1000 Genomes reference samples. Plots were generated using the LocusZoom website (54). Genetic positions 
refer to GRCh37/hg19 coordinates. Forest plots of the respective lead SNPs are provided in B and D, with ORs and their 95% confidence intervals plot-
ted on the x axis. I2 is the percentage of total variation across studies that is due to heterogeneity.
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Given the high prevalence of  ERP in the general population and a high MAF of  the identified genetic 
variants in our study the key question remains of  why only a very small subset of  individuals develops 
severe ventricular arrhythmias and ERS. The fine interplay of  a genetic predisposition and specific precip-
itating conditions might lead to an electrically vulnerable cardiac state. Insights into the potential origin of  
ventricular arrhythmias in ERS come from animal models and highlight the role of  different ion channels, 
including Ito (10). A pharmacological model of  ERS in canine wedges from the inferior and lateral ventricu-
lar wall showed marked regional dispersion of  repolarization (loss of  phase 2 AP dome and AP shortening 
Table 3. The 43 genome-wide significant SNPs of the KCND3 locus
SNP Position Location A1/A2 AF1 OR P
rs817972 112,399,057 Intron a/g 0.90 1.35 [1.22–1.50] 2.0 × 10–8
rs583731 112,421,854 intron t/c 0.09 0.69 [0.62–0.77] 3.6 × 10–11
rs528779 112,424,077 Intron t/c 0.71 1.18 [1.11–1.25] 2.0 × 10–8
rs612790 112,426,577 Intron c/g 0.29 0.84 [0.80–0.89] 1.1 × 10–8
rs2813862 112,427,918 Intron c/g 0.29 0.84 [0.79–0.89] 5.9 × 10–9
rs1767283 112,428,953 Intron t/c 0.29 0.84 [0.80–0.89] 8.5 × 10–9
rs11102354 112,433,666 Intron a/g 0.31 1.18 [1.11–1.25] 3.3 × 10–8
rs605604 112,433,863 Intron a/c 0.70 1.19 [1.12–1.26] 6.4 × 10–9
rs2798334 112,437,344 Intron t/c 0.30 0.84 [0.79–0.89] 7.7 × 10–9
rs2813864 112,437,853 Intron a/g 0.29 0.84 [0.79–0.89] 8.2 × 10–9
rs2587368 112,437,907 Intron t/c 0.40 0.86 [0.81–0.90] 1.7 × 10–8
rs2813865 112,437,956 Intron a/g 0.25 0.82 [0.77–0.87] 8.6 × 10–10
rs894849 112,437,964 Intron t/c 0.41 0.86 [0.81–0.90] 1.3 × 10–8
rs608673 112,439,757 Intron t/c 0.44 0.86 [0.81–0.91] 2.0 × 10–8
rs7539683 112,439,770 Intron t/g 0.27 1.20 [1.13–1.27] 2.0 × 10–9
rs1805222 112,440,983 Intron a/g 0.27 1.20 [1.13–1.27] 3.3 × 10–9
rs2120436 112,451,447 Intron t/c 0.32 0.82 [0.78–0.87] 1.7 × 10–11
rs2034124 112,451,681 Intron a/g 0.45 1.16 [1.10–1.22] 1.6 × 10–8
rs12090194 112,454,822 Intron t/c 0.32 0.82 [0.78–0.87] 9.3 × 10–12
rs72692596 112,455,415 Intron t/c 0.32 0.84 [0.79–0.89] 2.8 × 10–9
rs72692597 112,455,442 Intron t/g 0.32 0.84 [0.79–0.89] 2.9 × 10–9
rs4839182 112,456,538 Intron a/g 0.55 1.18 [1.12–1.25] 3.9 × 10–9
rs4839183 112,456,882 Intron a/g 0.46 1.17 [1.11–1.23] 5.3 × 10–9
rs72692602 112,458,833 Intron t/c 0.68 1.20 [1.13–1.27] 2.5 × 10–9
rs72694603 112,458,893 Intron t/c 0.32 0.83 [0.79–0.89] 2.3 × 10–9
rs4839184 112,460,221 Intron c/g 0.32 0.83 [0.78–0.87] 2.6 × 10–11
rs4839185 112,460,262 Intron t/c 0.68 1.21 [1.15–1.28] 1.4 × 10–11
rs1443926 112,461,902 Intron a/g 0.68 1.21 [1.15–1.28] 2.0 × 10–11
rs6682872 112,462,984 Intron a/g 0.60 1.18 [1.12–1.24] 9.6 × 10–10
rs4838926 112,463,323 Intron c/g 0.40 0.85 [0.81–0.90] 2.0 × 10–9
rs4838927 112,463,617 Intron t/c 0.60 1.18 [1.12–1.24] 1.7 × 10–9
rs1545300 112,464,004 Intron t/c 0.32 0.82 [0.78–0.87] 7.7 × 10–12
rs17029069 112,464,376 Intron t/c 0.30 1.21 [1.14–1.28] 1.1 × 10–10
rs12119724 112,468,814 Intron t/c 0.29 1.21 [1.14–1.28] 7.3 × 10–11
rs11588747 112,470,474 Intron t/c 0.70 1.19 [1.12–1.27] 1.5 × 10–8
rs2010749 112,470,581 Intron t/c 0.63 1.20 [1.14–1.27] 3.7 × 10–11
rs1443927 112,471,029 Intron c/g 0.69 1.20 [1.14–1.28] 1.9 × 10–10
rs12145374 112,480,536 Intron a/c 0.80 1.22 [1.14–1.30] 8.6 × 10–9
rs72694622 112,481,667 Intron t/c 0.18 0.81 [0.75–0.87] 3.6 × 10–8
rs12144965 112,484,962 Intron t/c 0.82 1.23 [1.14–1.32] 2.8 × 10–8
rs3008527 112,523,095 Intron t/c 0.70 1.19 [1.12–1.26] 5.8 × 10–9
rs3008528 112,527,869 Intron a/t 0.70 1.18 [1.11–1.25] 1.7 × 10–8
rs2075811 112,530,626 Intron c/g 0.30 0.85 [0.80–0.90] 1.7 × 10–8
A1, effect allele; AF1, allele frequency of A1; position on chromosome 1 (build 37, GRCh37); OR, OR of A1 [95% confidence interval]; P, association P value 
of the Z test. The SNPs are ordered by their position, and the results of the combined meta-analysis are given. 
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in some epicardial regions but not others). Presence of  transmural repolarization heterogeneity allowed 
local reexcitation in form of  closely coupled extrasystolic activity (phase 2 reentry). The combination of  an 
arrhythmogenic substrate, represented by regional electrical instability, and triggering premature ventricular 
beats resulted in ventricular fibrillation (10). Data from ERS patients suggest that, in a subgroup, the ERP 
is due to a pure repolarization phenotype and arrhythmia (35) is triggered by Purkinje fiber ectopic beats.
Genetic variants in various ion channel genes have been associated with ERS (16), including the 
KCNJ8 and ABCC9 genes encoding the Kir6.1- and ATP-sensing subunits of  the KATP channel (6, 12, 41, 
42). The commonly implicated variant KCNJ8-p.S422L has a population frequency not consistent with 
ERS and is predicted to be benign by multiple in silico algorithms according to the ClinVar database (43). 
A recent study by Chauveau et al. has, however, identified a de novo duplication of  the KCND3 gene in 
a patient who survived sudden cardiac death and in his 2-year-old daughter (13). Both exhibited marked 
ERP in the inferolateral leads that was augmented by bradycardia and pauses in heart rhythm, in keeping 
with a repolarization mechanism underlying the ERS phenotype. Studies have suggested that the inferior 
region of  the left ventricle has a higher density of  KCND3 expression and higher intrinsic levels of  Ito (10). 
Figure 3. Colocalization results. Illustrations of the SMR test 
for the early repolarization pattern (ERP) risk and the expression 
quantitative trait loci (eQTLs) at the rs1545300 locus at chromo-
some 1p13.2 for the (A) left ventricle of the heart, (B) tibial artery, 
and (C) minor salivary gland tissue. The sample sizes for the eQTLs 
are n = 272, n = 388, and n = 85 in A, B, and C, respectively. In A–C, 
the GWAS regional association plot with ERP risk of the combined 
GWAS (n = 39,456), with level of significance of the SMR test (y 
axis) for each transcript in the locus indicated by a diamond posi-
tioned at the center of the transcript is shown (top). A significant 
SMR test represented by a purple diamond indicates an association 
of the transcript level of the respective genes (purple label) with 
the trait. For all 3 tissues, an increased gene expression level shown 
by a significant SMR test was associated with a higher risk of ERP. 
A filled purple diamond indicates a HEIDI test P > 0.05 and, thus, 
a likely colocalization. The regional association distribution with 
changes in expression of the highlighted (purple) gene transcript 
in the respective tissue is shown below. The x axis shows GRCh37/
hg19 genomic coordinates throughout.
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This may explain the higher vulnerability of  this region for the development of  ERS in the setting of  a 
genetically mediated gain of  function in the Ito current. Moreover, observational studies also identified 
different ERP subtypes, including the occurrence of  ERP in the inferior region and a horizontal/descend-
ing ST segment morphology associated with a higher risk of  sudden arrhythmic death and cardiovascular 
mortality (2, 44, 45). However, in a subgroup of  our study, the association signal of  ERP risk and KCND3 
variation was not dominated by a specific ERP high-risk subtype. Of  note, the formation of  subgroups led 
to reduction in sample size and thus statistical power.
Taken together, the rare occurrence of ERS may be explained by different conditions. On the one hand, 
an underlying monogenic mutation may be found in some cases. On the other, no single causal mutation can 
be identified in the majority of ERS cases, rendering the influence of multiple genes and environmental factors 
more likely, i.e., a “multihit condition.” Similar to other polygenic diseases, the sum of multiple minor effects 
of several common genetic variations together with specific external triggers may affect the occurrence of ERS. 
There is indeed evidence to suggest that common variants in the KCND3 locus increase arrhythmogenicity. 
A phenome-wide lookup of our common lead SNP in more than 450,000 individuals from the UK Biobank 
linked the minor T allele associated with reduced ERP to a reduced risk of heart arrhythmia (31). Furthermore, 
additional data show an association of the same common variant with reduced risk of atrial fibrillation (27, 
28). A small effect of a common SNP at KCND3 does not necessarily mean that the variant is benign; rather, 
a single risk allele is associated with a small but effective change in the gene expression level. Thus, the overall 
effects of the KCND3 gene expression levels on the phenotype may appear much stronger compared with the 
small effect of rs1545300. Based on our results, it could be hypothesized that variation in KCND3 gene expres-
sion levels and subsequently its encoded protein may affect the risk of ERP and eventually ERS. The positive 
effect direction of the change in KCND3 gene expression levels in heart tissue on the risk of ERP estimated 
via the SMR test (Supplemental Table 5) suggested an elevated risk, with increasing abundance of the KCND3 
encoded protein. Functional validation is necessary to validate this hypothesis, and analyses of the KCND3 
gene in individuals with ERS are warranted to confirm the role of KCND3 variation in arrhythmogenesis.
Our study has some limitations that need to be acknowledged. The presence of  ERP in the ECG can 
be variable, as it has been described to be dependent on age, heart rate, vagal activity, and medication, 
although our findings were valid after adjusting for some of  these factors. Therefore, we cannot exclude 
that we have missed some individuals with ERP. Second, the tissue-specific gene expression data used for 
the colocalization analysis are based on a limited sample size. A larger gene expression sample or func-
tional studies are needed to validate the revealed effect of  KCND3 expression on the ERP. In addition, we 
analyzed only common and low-frequency SNPs with a MAF >1% missing rare variants and variants not 
included in the imputation panel. Finally, long-term outcome data identifying those individuals with ERP 
who suffer from ERS are not available. Further GWAS in large international collaborative cohorts of  ERS 
patients are therefore necessary to determine the genetic risk.
In conclusion, we show for the first time to our knowledge, a robust association of  genetic variants with 
the ERP in a large GWAS of  individuals of  European ancestry. The locus in the KCND3 ion channel gene 
is an intuitive candidate and supports the theory that at least a proportion of  ERS is a pure channelopathy. 
Intensive future research will be needed to extend the discovery of  ERP susceptibility loci to individuals 
of  non-European ancestry and to improve identification and risk stratification of  the subset of  individuals 
with the ERP who are at highest risk for potentially lethal ventricular arrhythmias.
Methods
Study cohorts and SNP genotyping. The discovery stage included 25,822 subjects (2,181 ERP cases) from 
8 independent cohorts with genetic and phenotypic data available for analyses: the British Genetics 
of  Hypertension (BRIGHT) study, the Gutenberg Health Study (GHS1, GHS2), the Genetic Regula-
tion of  Arterial Pressure In humans in the Community (GRAPHIC) study, the Lifelines Cohort Study, 
the Study of  Health in Pomerania (SHIP, SHIP-Trend), and TwinsUK. An additional 13,634 subjects 
(1,124 ERP cases) from 4 cohorts (Rotterdam Study I, II, III, and Cooperative Health Research In 
South Tyrol [CHRIS] study) were used for independent replication: the Rotterdam Study (Rotterdam 
Study I, II, III) and the CHRIS study. The included subjects of  all cohorts were of  European ancestry, 
and all cohorts but BRIGHT (which sampled hypertensive cases) were population based (Supplemental 
Table 6). The determination of  the discovery and replication cohorts was determined upfront based on 
the timeline of  the availability of  the genetic and ERP data.
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ECG analysis and ERP evaluation. Twelve-lead ECGs of  all twelve studies were obtained during a study 
visit in a supine position after approximately 5 minutes of  rest and were analyzed manually by experi-
enced and specifically trained cardiologists for the presence of  ERP. In detail, ECGs from TwinsUK and 
BRIGHT were evaluated in the United Kingdom, and ECGs from all other cohorts were evaluated in Ger-
many. Paper-printed 12-lead ECGs were independently read by 2 experienced clinicians who were blinded 
with respect to age and sex. There was very high level of  agreement between each pair of  interpreters 
(95%–98%) (20, 21). Cases of  ambiguous or unequal phenotype were jointly reassessed by 2 readers, and a 
consensus decision was achieved. To determine interobserver variability between the United Kingdom and 
German teams, a subset of  ECGs was analyzed by both teams, yielding a concordance of  96% (20, 21).
The ERP phenotype was established according to the definition by Haïssaguerre and Macfarlane 
(6, 23). ERP was defined as elevation of  the J point above the level of  QRS onset of  ≥0.1 mV in at least 
2 corresponding leads. To avoid confusion or overlap with Brugada syndrome or arrhythmogenic right 
ventricular dysplasia, leads V1–V3 were excluded from ERP scoring. In case of  presence of  ERP, region 
(inferior: leads II, III, aVF; anterolateral: leads I, aVL; V4–V6, or both) and the maximum amplitude of  J 
point elevation were documented. Further, the morphology of  ERP was assessed as notching, slurring, or 
both; additionally, the ST segment was assessed according to Tikkanen and colleagues (44) as either con-
cave/rapidly ascending (>0.1 mV elevation 100 ms after J point peak or persistently elevated ST segment 
>0.1 mV) or horizontal/descending (≤0.1 mV elevation within 100 ms after J point peak) (23, 44). In 
case of  a QRS duration of  >120 ms or rhythm other than sinus rhythm (e.g., atrial fibrillation, pacemaker 
stimulation) ECGs were excluded from the analysis.
GWAS in individual studies. The GWAS in each study for both the discovery and replication stage was 
performed on autosomal imputed SNP genotypes using study-specific quality control protocols that are 
provided in detail in Supplemental Table 6. Association analyses were performed using logistic regression 
for ERP status as outcome and an additive genetic model on SNP dosages, thus taking genotype uncer-
tainties of  imputed SNPs into account. The analyses were adjusted for age, sex, and relevant study-specific 
covariates, such as principal components for population stratification (Supplemental Table 6).
Meta-analysis of  individual study GWAS results. The result files from individual cohorts’ GWAS underwent 
extensive quality control before meta-analysis using the gwasqc() function of  the GWAtoolbox package v2.2.4 
(46, 47). The quality control included file format checks as well as plausibility and distributions of  association 
results, including effect sizes, standard errors, allele frequencies, and imputation quality of  the SNPs.
The meta-analyses were conducted using a fixed-effect inverse variance weighting as implemented in 
Metal (48). Monomorphic SNPs, SNPs with implausible association results (i.e., P ≤ 0, SE ≤ 0, |log(OR)| 
≥ 1000), and SNPs with an imputation quality score ≤0.4 were excluded prior to the meta-analyses, result-
ing in a median of  12,839,202 SNPs per cohort (IQR: 10,756,073–13,184,807). During the meta-analysis, 
the study-specific results were corrected by their specific λGC if  > 1. Results were checked for possible errors 
like use of  incorrect association model by plotting the association P values of  the analyses against those 
from a Z score based meta-analysis for verifying overall concordance. SNPs that were present in <75% of  
the total sample size contributing to the respective meta-analysis or with a MAF ≤0.01 were excluded from 
subsequent analyses. Finally, data for up to 6,976,246 SNPs were available after the meta-analysis.
Quantile-quantile plots of  the meta-analysis results are provided in Supplemental Figure 2. To assess 
whether there was an inflation of  P values in the meta-analysis results attributed to reasons other than 
polygenicity, we performed LD score regression (49). The LD score–corrected λGC value of  the discovery 
and replication combined meta-analysis was 1.01, supporting the absence of  unaccounted population strat-
ification. Genome-wide significance was defined as P < 5 × 10–8, corresponding to a Bonferroni correction 
of  1 million independent tests (50). The I2 statistic was used to evaluate between-study heterogeneity (51).
To evaluate the presence of  allelic heterogeneity within each locus, the GCTA stepwise model selection 
procedure (cojo-slct algorithm) was used to identify independent variants using a step-wise forward selec-
tion approach (52). We used the genotype information of  4,081 SHIP individuals for LD estimation and set 
the significance threshold for independent SNPs to 5 × 10–8.
All loci were named according to the nearest gene of  the lead SNP. Genomic positions correspond to 
build 37 (GRCh37).
Replication analysis. To minimize the burden for multiple testing correction and thus maximizing the 
power for replication, the lead SNPs of  genome-wide significant loci in the discovery stage were taken 
forward to the replication stage in independent samples (Table 1). SNPs were considered as replicated if  
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the P value of  a 1-sided association test was <0.025, which corresponds to a Bonferroni correction for the 
2 lead SNPs tested at 5% significance level.
Finally, the GWAS results from the discovery and replication studies were meta-analyzed to search for 
additional genome-wide significant loci by maximizing the statistical power for locus discovery.
Gene expression–based analyses. The lead SNP, rs1545300, of  the KCND3 locus of  the combined dis-
covery and replication GWAS meta-analysis was tested for cis eQTLs (±1-Mb window around the tran-
scription start site) in 48 tissues available in the GTEx v7 database that included at least 70 samples. 
Significant associations were selected based on a Bonferroni-corrected P < 3.0 × 10–5 for the number of  
genes and tissues tested.
Subsequently, the SNP rs1545300 was tested and plotted for colocalization in the 3 tissues with an 
eQTL FDR < 0.2 by applying the SMR method (53) using the GWAS and GTEx eQTL summary statis-
tics. The method includes a test of  whether the effect on expression observed at a SNP or at its proxies 
is independent of  the signal observed in the GWAS, i.e., that gene expression and y are associated only 
because of  a latent nongenetic confounding variable (SMR test), and a second test that evaluates if  the 
eQTL and GWAS associations can be attributable to the same causative variant (HEIDI test). Signifi-
cance for colocalization of  gene expression and the GWAS signals was defined by PSMR < 0.01, where 
additionally a PHEIDI ≥ 0.05 indicates the same underlying causal variant (53).
Data availability. Summary association results of  the combined GWAS meta-analysis have been sub-
mitted for full download to the CHARGE dbGaP website under accession phs000930 (https://www.ncbi.
nlm.nih.gov/gap).
Statistics. Unless stated otherwise, the analyses were conducted and plotted using R statistical software 
(46), a Z test was applied, and all reported P values are 2 sided. P values of  less 0.05 after correction for mul-
tiple testing were considered significant.
Study approval. The BRIGHT study ethics committee approval was obtained from the multiple local 
research committees of  the partner institutes from Aberdeen, Glasgow, London, Cambridge, and Oxford 
in the United Kingdom. The GHS study followed the recommendations of  the Declaration of  Helsinki 
and approval was obtained by the local data protection officer and ethics committee of  the Chamber of  
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